Introduction
============

Both environmental and genetic components are responsible for the pathogenesis of nasopharyngeal carcinoma (NPC) [@B1]. Epstein-Barr virus (EBV) infection is related to the development of NPC, a prevalent head and neck tumor in Taiwan and southern Asia [@B2]. On the basis of modern World Health Organization (WHO) tumor categorization, the correlation is high and predominant in differentiated as well as undifferentiated non-keratinizing carcinomas [@B3]. In NPC patients, recent progressions have been made in imaging diagnosis, radiation treatment, adjuvant chemotherapy and neoadjuvant chemotherapy. These treatments enhance locoregional cure, nevertheless, therapeutic alternatives for progressive NPCs are still insufficient [@B4], although the additional neoadjuvant chemotherapy plus concurrent chemoradiotherapy is associated with reduced distant failure as compared with concurrent chemoradiotherapy alone [@B5]. Moreover, chemoradiotherapy-induced hemoglobin decrease has negative influence on locoregional control and survival [@B6]. In keeping with the American Joint Committee on Cancer (AJCC, 7^th^ edition) stratification, primary tumor, nodal status and metastasis continue to be critical prognostic elements [@B3], [@B4]. Thus, to detect potential biomarkers with improved associations to malignancy development and/or medication results in NPC patients are indispensable. Novel markers will be helpful to classify and explore novel therapeutic targets for NPC [@B7].

Data mining on a generally-acknowledged expression profile in the Gene Expression Omnibus dataset (GEO, NCBI, Bethesda, MD, USA) was accordingly performed. Among three potential transcripts that were considerably higher expressed in human NPCs, transient receptor potential cation channel, subfamily A, member 1 (*TRPA1*) presented the highest log~2~ ratio (*P* \< 0.0001) and a correlation coefficient with the tumor stage (*P*= 0.0002). The *TRPA1* gene belongs to the TRP channel family, encoding integral membrane proteins that functions as cation channels. So far, about 30 TRPs have been recognized. Through protein homology and channel function, these TRPs are characterized into seven distinct subfamilies: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), TRPA (ankyrin transmembrane protein) and, TRPN (NomPC-like). Genes encoding TRP ion channels are broadly expressed in various tissues and cell categories [@B8]. These genes participate in distinctive physiological processes, for example, the perception of diverse stimuli or ion homeostasis [@B9], [@B10].

Except for a few are high Ca^2+^-selective and some are even permeable, for greatly hydrated Mg^2+^ ions, most TRPs are non-selective cation channels. A standard TRP protein consists of six putative transmembrane α-helices (S1 to S6) and surrounded by cytoplasmic N and C terminals, with a pore-shaping reentrant loop between S5 and S6 [@B11]-[@B13]. Lately, TRP channels were reported to engage in the activation of cell proliferation and abnormal differentiation, as well as resistance to apoptosis. These aspects result in tumor growth and progression [@B14]. Numerous TRP channel genes, *TRPC1*, *TRPC3*, *TRPC4*, *TRPC5*, *TRPC6*, *TRPM2*, *TRPM4*, *TRPM7*, *TRPM8*, *TRPV1*, *TRPV2*, *TRPV4* and *TRPV6*, have been reported to play oncogenic roles in cancer cells, including the carcinoma of lung, breast, prostate, ovarian, gastric, liver, nasopharyngeal, glioblastoma and melanoma [@B15]. Yet, the immunoexpression of TRPA1 in a considerable set of biopsies from NPC tissues and its correlation with various clinicopathological parameters have not been carefully evaluated. Hence, the aim of this investigation was to inspect their relationships.

Materials and methods
=====================

Analysis of expression profile
------------------------------

Firstly, we identified a database (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE12452>), containing the results of 31 biopsies of NPCs along with 10 health nasopharyngeal tissues which were analyzed by the Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). To calculate the expression values of all transcripts, original CEL files were introduced into the Nexus Expression 3 software (BioDiscovery, EI Segundo, CA, USA). Devoid of prior selection and filtering, the entire probe series were utilized in the computation. Based on tissue types \[NPCs vs. non-tumor tissues; high-stage (stage III) vs. low-stage (stage I-II) NPCs\], comparative analysis with supervision was executed, to determine the significantly and differentially expressed genes, i.e., critical transcripts in the pathogenesis and progression of NPC. Those transcripts with *P*≤ 0.005 and log~2~-transformed expression fold-change \> 1 are listed in Table [1](#T1){ref-type="table"}.

Patients and tumor samples
--------------------------

Tissues from NPC patients were formalin-fixed, permitted by the institutional review board and used in this survey (IRB1030213). Paraffin-embedded tissues were created from 124 NPC patients. Biopsies of these patients were undertaken during January 1993 to December 2002. Distant metastasis was not shown in any individual during initial presentation. The tumor staging and histological subtypes were reassessed according to the 7^th^ AJCC procedure and the current WHO classification by two pathologists, objectively.

Immunohistochemistry
--------------------

From paraffin-embedded tissue blocks, tissue sections (3-μm thickness) were cut onto precoated slides. Xylene and ethanol were used to deparaffinize and rehydrate the slides. To retrieve antigens, slides were microwaved in the 10-mM citrate buffer (pH 6.0; 7 min). Saline was used to buffer endogenous peroxidase. Slides were then developed using a goat polyclonal primary antibody probing TRPA1 (sc-32353, Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution ratio of 1:25 (1 h). The ChemMate™ DAKO EnVision™ Detection Kit (K5001, Carpinteria, CA, USA) was applied to detect the primary antibody. The slides were next treated with an anti-goat secondary antibody for 30 min and 3,3-diaminobenzidine for 5 min. Thereafter, Gill\'s haematoxylin was applied for counterstaining. Without knowing any clinical and follow-up data, the immunostaining of the TRPA1 protein were examined blindly by two pathologists (CF Li and TJ Chen). In the cytoplasm and cell membrane of the tumor cells, immunoreactivities were assessed with the joint of the intensity and percentage of positively stained tumor cells. To produce the H-score, the equation, H-score = Σ*P~i~*(*i*+1), was used. *Pi*stands for the percentage while *i* is the intensity of cancer cells stained by the anti-TRPA1 antibody (0 to 3+). The intensity varied from 0 to 100%. H-score \> median of total specimens were designated as high TRPA1 expression level.

Patient medication and clinical characteristics
-----------------------------------------------

Every patient with follow-up for consequence accepted an entire program of radiotherapy (total dose ≥ 7,000 cGy). In patients with stages II-IV, cisplatin-based chemotherapy was additionally treated according to the former procedure [@B14]. The process of radiotherapy was overall constant during this time slot. Each patient was consistently censored following radiation therapy till expiration or his/her final appointment. The average follow-up interval was 59.6 months, spanning 4-117 months.

Statistics
----------

The SPSS V.14.0 software (SPSS Inc. Chicago, IL, USA) was used to conduct statistical analyses. To test the independence between TRPA1 protein expression level and different clinicopathological parameters, Chi-square test was applied. Disease-specific survival, distal metastasis-free survival, and local recurrence-free survival are the endpoints that were analyzed. These were determined from the beginning day of radiation therapy, to the day of event occurred. Cases without patient clinical characteristics were inspected at the final day of follow-up. To plot survival curves and estimate the prognostic variations between patient clusters, Kaplan-Meier technique and the log-rank test were used. With the Cox proportional hazard model, multivariate analysis was carried out. Nevertheless, primary tumor and nodal status (both are AJCC components) were not incorporated in multivariate estimations. Two-tailed analyses of significance were employed and *P* \< 0.05 was regarded as statistical significance for all calculations.

Results
=======

The *TRPA1* transcript was considerably upregulated in NPCs deposited in the public database
--------------------------------------------------------------------------------------------

From GSE12452 deposited in GEO database containing 10 normal and 31 NPC tissues, we found that five probes representing three transcripts were significantly upregulated in tissues from NPC patients, compared to those from normal tissues (*P* \< 0.0001; Table [1](#T1){ref-type="table"}). Of these transcripts, the expression level of *TRPA1* mRNA also revealed a stepwise upregulation in low- to high-stage NPCs (*P*= 0.0002; Fig. [1](#F1){ref-type="fig"}). Therefore, immunoexpression and clinical significances of *TRPA1* in a larger cohort was further studied.

Immunoexpression of TRPA1 and its correlation with clinicopathological parameters in NPC specimens
--------------------------------------------------------------------------------------------------

Thoroughly, 124 patients with NPC containing five keratinizing squamous cell, 54 non-keratinizing differentiated, and 65 non-keratinizing, undifferentiated carcinomas were studied. With an average age of 48.6 years (ranging from 20 to 83 years), this cohort contains 95 males and 29 females. Thirty-eight patients were categorized into AJCC stages I-II; 86 were stages III-IV (Table [2](#T2){ref-type="table"}). Immunoexpression of the TRPA1 protein was distinctly examined in each specimen. The TRPA1 protein was barely detected in a normal nasopharyngeal mucosa (Fig. [2](#F2){ref-type="fig"}A). Due to the H-score of 62 patients were examined to be lower than the median value, these events were classified as TRPA1 low expression (Fig. [2](#F2){ref-type="fig"}B). Additional 62 specimens showed distinguishing TRPA1 immunostaining, with the H-score higher than the median value (Fig. [2](#F2){ref-type="fig"}C). As shown in Table [2](#T2){ref-type="table"}, high TRPA1 protein levels were significantly correlated to those specimens with advanced primary tumor (T3-T4; *P* = 0.009) and higher AJCC stage (*P* = 0.019). In contrast, other clinicopathological parameters were not meaningfully correlated with the TRPA1 protein level (Table [2](#T2){ref-type="table"}).

The prognostic effect of TRPA1 protein levels on NPCs
-----------------------------------------------------

As shown in Table [3](#T3){ref-type="table"}, NPC patients with lower primary tumor (T1-T2), nodal status (N0-N1) and AJCC stage (I-II) ensured better disease-specific survival (*P* = 0.0289; *P* = 0.0008; *P* = 0.0020), distal metastasis-free survival (*P* = 0.0085; *P* = 0.0132; *P* = 0.0072) and local recurrence-free survival (*P* = 0.0180; *P* = 0.0160; *P* = 0.0026), within a medium period of 64 months. Moreover, high TRPA1 protein levels were convincingly prognostic of disease-specific survival (*P* = 0.003), distal metastasis-free survival (*P*= 0.0005) and local recurrence-free survival (*P* = 0.0026) (Fig [3](#F3){ref-type="fig"}). Next to AJCC tumor stage [@B16], a high TRPA1 protein level steadily served as a negative prognostic indicator for disease-specific survival (*P* = 0.014; hazard ratio = 2.297), distal metastasis-free survival (*P* = 0.004; hazard ratio = 2.471) and local recurrence-free survival (*P* = 0.017; hazard ratio = 2.335) in multivariate analysis (Table [4](#T4){ref-type="table"}). Therefore, the protein level of TRPA1 represents as an independent prognostic marker.

Discussion
==========

In the current report, we showed that upregulation of TRPA1 protein can be a strong prognostic marker for disease-free, distal metastasis-free and local recurrence-free survivals in a cohort of 124 NPC patients. As a matter of fact, the expression patterns of other TRP channel members have been suggested to be biomarkers for diagnosis and/or prognostics in different cancers. For instance, high TRPC6 expression in esophageal squamous cell carcinoma was reported, and it is essential for cell propagation and the progression of cell cycle [@B17]. In metastatic breast cancer, TRPV6 and TRPM7 may act as biomarkers by correlation with detrimental outcome [@B18].

The \'wasabi receptor\', i.e., TRPA1, plays a crucial part in somatosensation across diverse evolutionary phyla, including vertebrates and invertebrates [@B10]. In mammalian pain pathway, the TRPA1 protein is mainly expressed on primary afferent neurons. At these locations, TRPA1 works as a sensor of exogenous and endogenous chemical stimulants, for example, allyl isothiocyanate (AITC), acrolein, and 4-hydroxynonenal [@B19]-[@B22]. In human small cell lung cancer (SCLC), *TRPA1* mRNA levels were markedly upregulated in tumor specimens, compared to normal lung tissues and non-SCLC samples. In vitro treatment with AITC, a volatile toxic substance, on respiratory system-derived SCLC cell lines, caused an increment of the concentration of intracellular calcium. This effect could be hampered by a specific antagonist of TRPA1, AP18. Through SRC proto-oncogene, non-receptor tyrosine kinase- and calcium-dependent machineries, AITC and formalin activated mitogen-activated protein kinase 1/3 \[MAPK1/3, also known as extracellular signal regulated kinase 1/2 (ERK1/2)\] in SCLC-derived TRPA1-positive H146 cells. Particularly, knockdown of the *TRPA1* gene seriously damaged anchorage-independent cell growth in H146 cells [@B23]. For the first time, we found that the upregulation of TRPA1 protein correlates with the development and progression of NPC, but whether TRPA1 plays similar roles in NPC-derived cells to those of SCLC-derived cells remains to be elucidated.

Significantly increased hazard ratios of advanced AJCC stage (III-IV) and disease-specific, distal metastasis-free and local recurrence-free survivals in NPC patients were identified, similar to another investigation [@B24] and our previous studies [@B16], [@B25], [@B26]. Further, substantial correlations between TRPA1 protein levels and primary tumor in addition to the AJCC stage, reinforced that upregulation of TRPA1 protein may be responsible for NPC progression. Indeed, the intestinal inflammation associated with colon cancer is a well-known situation [@B27]. In mice, activation and sensitization of TRPA1 induced and maintained colitis [@B28]. Moreover, the *TRPA1* mRNA level was upregulated in inflamed gut [@B29]. Accordingly, TRPA1 may serve as a high priority target via regulation of inflammation in the treatment of NPC.

Our study further indicated that the level of TRPA1 protein in biopsy specimens may anticipate a response to the traditional treatment on NPCs, as concurrent radiochemotherapy has no beneficial effects for quite a few NPC patients. In 4 years, about 30% to 40% of patients acquire metastatic properties. When metastasis arises, the prospect is extremely unfavorable [@B30]. It has been identified that extracellular molecules released by injured or inflammatory tissues regulate TRP channel members, including TRPV1, TRPV2, TRPV3, TRPV4, TRPM8 as well as TRPA1 [@B31]. Cell proliferation, invasion, migration and angiogenesis deeply implicate in tumor development [@B32]. These activities are partially regulated by calcium homeostasis including TRP cation channels [@B33]-[@B37]. By aiming at calcium homeostasis in cancer therapy, carboxyamidotriazole (CAI) was one pioneer drug in clinical trial [@B38]. CAI is a synthetic blocker of calcium influx and it displayed anti-angiogenic, -proliferative and -metastatic abilities in vitro. Nevertheless, treatment with CAI alone was not able to improve survival or quality of life in clinical trials in renal cell carcinoma [@B39], glioblastoma multiforme [@B40] and non-small cell lung cancer [@B41]. On the other hand, a consolidation of CAI and paclitaxel (a standard chemotherapy agent that targets tubulin, inhibits the disassembly of microtubules and cell division) enhanced anti-tumor activity in ovarian cancer [@B42]. While NPC varies from other carcinomas in its etiology and probable therapeutic alternatives, the results from our study implied that TRPA1 may be a novel molecular target for chemotherapy.

In conclusion, we conducted analysis of expression profile and assessment of TRPA1 expression in a cohort of 124 NPC patients. The TRPA1 protein levels could be detected by immunohistochemistry in all cases, in spite of the H-score varies a lot individually. In addition to the higher primary tumor, TRPA1 upregulation is independently and negatively predictive disease-specific, distal metastasis-free and local recurrence-free survivals. Therefore, TRPA1 signifies one valuable prognostic marker in patients with NPC, especially those who were remedied with radiation therapy and adjuvant cisplatin chemotherapy.
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![A heat map showed that data analysis on GSE12452 (GEO dataset) detected *TRPA1* transcript constantly upregulated (*P* \< 0.0001) in tissues from NPC, compared to those from normal ones, and *TRPA1* transcript showed a stepwise upregulation in low- to high-stage NPCs. Sample identities of normal (*n* = 10) and tumor (*n*= 31) are indicated. Green, dark and red represent low, intermediate and high expression values.](jcav07p1181g001){#F1}

![Representatives of the TRPA1 immunoexpression in normal and tumor tissues of NPC patients. In a normal nasopharyngeal mucosa, TRPA1 was not detected (A), (B) NPC tissues with low expression (H-score ≤ median) and (C) high TRPA1 staining (H-score \> median).](jcav07p1181g002){#F2}

![Kaplan-Meier estimator plotted the prognostic denotation of the TRPA1 protein levels for disease-specific, distal metastasis-free and local recurrence-free survivals (A-C).](jcav07p1181g003){#F3}

###### 

Summary of top 3 differentially expressed transcripts associated with both initiation and progression of NPC in the transcriptome of nasopharyngeal carcinoma.

  Gene Symbol    Probe          Comparing tumor to non-tumor   Comparing high to low stage^&^   Gene Name   Molecular Function                                                                        
  -------------- -------------- ------------------------------ -------------------------------- ----------- -------------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  *TRPA1*        217590_s-at    1.3009                         0.0003                           2.0258      \< 0.0001            Transient receptor potential cation channel; subfamily A; member 1   Calcium channel activity, calcium ion binding, channel activity, ion channel activity
  *C8orf42*      226778_at      1.2737                         \< 0.0001                        1.1512      0.0002               Chromosome 8 open reading frame 42                                   \-
  230903_s\_at   1.1358         \< 0.0001                      1.047                            0.0005                                                                                                
  *CALB1*        205626_s\_at   1.1786                         0.0013                           1.1036      0.0066               Calbindin 1; 28kDa                                                   Calcium ion binding, protein binding, vitamin D binding
  205625_s\_at   1.0469         0.0016                         1.0743                           0.0027                                                                                                

^&^, high stage: stage III; low stage: stage I and II.

###### 

Correlation between TRPA1 expression levels and important clinicopathologic variables.

  Parameter            Category           TRPA1 expression level   *P*-value   
  -------------------- ------------------ ------------------------ ----------- ---------
                                          Low                      High        
  Gender                                                                       
                       Male               48                       47          0.832
                       Female             14                       15          
  Age (years)                                                                  
                       \< 60              47                       51          0.378
                       ≥ 60               15                       11          
  Primary tumor (T)                                                            
                       T1-T2              47                       33          0.009\*
                       T3-T4              15                       29          
  Nodal status (N)                                                             
                       N0-N1              33                       23          0.071
                       N2-N3              29                       39          
  Stage                                                                        
                       I-II               25                       13          0.019\*
                       III-IV             37                       49          
  Histological grade                                                           
                       Keratinizing       3                        2           0.445
                       Non-keratinizing   30                       24          
                       Undifferentiated   29                       36          

\*, Statistically significant.

###### 

Univariate log-rank analysis.

  Parameters           Category                        *n*   DSS   DMeFS      LRFS                   
  -------------------- ------------------------------- ----- ----- ---------- ------ ---------- ---- ----------
  Gender                                                                                             
                       Male                            95    45    0.7870     38     0.6128     30   0.3240
                       Female                          29    14               11                7    
  Age (years)                                                                                        
                       \< 60                           98    48    0.8600     42     0.3091     29   0.8206
                       ≥ 60                            26    11               7                 8    
  Primary tumor (T)                                                                                  
                       T1-T2                           80    32    0.0289\*   25     0.0085\*   19   0.0180\*
                       T3-T4                           44    27               24                18   
  Nodal status (N)                                                                                   
                       N0-N1                           56    18    0.0008\*   17     0.0132\*   12   0.0160\*
                       N2-N3                           68    41               32                25   
  Stage                                                                                              
                       I-II                            38    10    0.0020\*   9      0.0072\*   5    0.0026\*
                       III-IV                          86    49               40                32   
  Histological grade                                                                                 
                       Keratinizing/Non-keratinizing   47    20    0.1980     17     0.2753     15   0.9521
                       Undifferentiated                77    39               32                22   
  TRPA1 level                                                                                        
                       Low (H-score \< median)         62    20    0.0003\*   16     0.0005\*   12   0.0026\*
                       High (H-score ≥ median)         62    39               33                25   

\*, Statistically significant; DSS, Disease-Specific Survival; DMeFS, Distal Metastasis-Free Survival; LRFS, local recurrence-free survival.

###### 

Multivariate survival analysis.

  Parameter     Category   DSS     DMeFS         LRFS                                                            
  ------------- ---------- ------- ------------- --------- ------- ------------- --------- ------- ------------- ---------
  Stage                                                                                                          
                I-II       1       \-            0.003\*   1       \-            0.034\*   1       \-            0.015\*
                III-IV     2.374   1.191-4.730             2.211   1.062-4.602             3.261   1.256-8.470   
  TRPA1 level                                                                                                    
                Low        1       \-            0.014\*   1       \-            0.004\*   1       \-            0.017\*
                High       2.297   1.328-3.972             2.471   1.346-4.535             2.335   1.161-4.696   
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